Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...

Indeed, Regeneron believes that the success with Ebola could potentially have ushered in “a new era in which monoclonal antibodies could be used to fight viral diseases and global pandemics.” ...

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

and anti-CD38 monoclonal antibody, and Regeneron is planning to file linvoseltamab in the same setting. Dosing could be another point of difference for the new drug. Elrexfio has a slight edge ...

Monoclonal antibodies now being used for chronic sinusitis ... Tversky disclosed relationships with Sanofi, Regeneron, AstraZeneca, and numerous other pharmaceutical companies.

Regeneron's drug is the only therapy approved ... and ACZ 885 (canakinumab), a fully humanized monoclonal antibody directed at IL-1β, from Novartis of Basel, Switzerland, currently in phase ...